evaluate high risk populations and monitor serum liver tests (5.1) Birth defects, decreased IQ, and neurodevelopmental disorders following in uteroexposure
Then, people start getting sick and occasionally go to the hospital
Drug treatment of overweight and obesity in PCOS Growing evidence supports the use of obesity medications, especially off-label use of glucagon-like peptide (GLP) 1 receptor agonists such as liraglutide, semaglutide, and exenatide, as they can improve the metabolic profile, reduce insulin stimulation on the ovary, and improve ovarian function and ovulation
In findings from the STEP TEENS phase 3a trial, adolescents aged 12 to 17 years with obesity or overweight and at least one weight-related coexisting condition were randomly assigned 2:1 to receive semaglutide 2.4 mg (Wegovy, Novo Nordisk) or placebo for 68 weeks